Immunity to Commensal Fungi: Detente and Disease

Annual Review of Pathology: Mechanisms of Disease

Volumn 12, Issue , 2017, Pages 359-385

  Wheeler, Matthew L ^a   Limon, Jose J ^a   Underhill, David M ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Aspergillus; Candida; Dectin 1; Innate immunity; Malassezia; Microbiome; Mycobiome

Indexed keywords

ADAPTIVE IMMUNITY; ASPERGILLUS; BLOODSTREAM INFECTION; CANDIDIASIS; CLADOSPORIUM; COMMENSAL; COMMENSAL FUNGUS; FUNGUS IMMUNITY; FUSARIUM; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE STATUS; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; LYMPHOCYTE RECIRCULATION; MACROPHAGE; MALASSEZIA; MONOCYTE; MOUTH INFECTION; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES; SERUM FACTOR; SIGNAL TRANSDUCTION; SKIN INFECTION; ANIMAL; COMPLICATION; DISEASE; FUNGUS; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; DISEASE; FUNGI; HUMANS; IMMUNITY, INNATE; MYCOSES;

EID: 85011281183     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-052016-100342     Document Type: Review

References (177)

1. Drummond RA, Gaffen SL, Hise AG, Brown GD. 2015. Innate defense against fungal pathogens. Cold Spring Harb. Perspect. Med. 5:a019620
2. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van Veerdonk FL. 2015. Immune defence against Candida fungal infections. Nat. Rev. Immunol. 15:630-42
3. Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, et al. 2010. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J. Exp. Med. 207:2907-19
4. Seed PC. 2015. The human mycobiome. Cold Spring Harb. Perspect. Med. 5:a019810
5. Underhill DM, Iliev ID. 2014. The mycobiota: interactions between commensal fungi and the host immune system. Nat. Rev. Immunol. 14:405-16
6. Ibrahim AS, Kontoyiannis DP. 2013. Update on mucormycosis pathogenesis. Curr. Opin. Infect. Dis. 26:508-15
7. Johnson L, Gaab EM, Sanchez J, Bui PQ, Nobile CJ, et al. 2014. Valley fever: danger lurking in a dust cloud. Microbes Infect. 16:591-600
8. Horwath MC, Fecher RA, Deepe GS Jr. 2015. Histoplasma capsulatum, lung infection and immunity. Future Microbiol. 10:967-75
9. Rohatgi S, Pirofski LA. 2015. Host immunity to Cryptococcus neoformans. Future Microbiol. 10:565-81
10. Tang J, Iliev ID, Brown J, Underhill DM, Funari VA. 2015. Mycobiome: approaches to analysis of intestinal fungi. J. Immunol. Methods 421:112-21
11. Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, et al. 2010. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLOS Pathog. 6:e1000713
12. Dupuy AK,David MS,LiL,HeiderTN, Peterson JD, et al. 2014. Redefining the human oral mycobiome with improved practices in amplicon-based taxonomy: discovery of Malassezia as a prominent commensal. PLOS ONE 9:e90899
13. Dollive S,Chen YY, Grunberg S, Bittinger K, Hoffmann C, et al. 2013. Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment. PLOS ONE 8:e71806
14. Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, et al. 2012. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336:1314-17
15. Sokol H, Leducq V, Aschard H, Pham HP, Jegou S, et al. 2016. Fungal microbiota dysbiosis in IBD. Gut. In press. doi:10.1136/gutjnl-2015-310746
16. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffiths AM, et al. 2015. Inflammation, antibiotics, and diet as environmental stressors of the gut microbiome in pediatric Crohn's disease. Cell HostMicrobe 18:489-500
17. Chehoud C, Albenberg LG, Judge C, Hoffmann C, Grunberg S, et al. 2015. Fungal signature in the gut microbiota of pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 21:1948-56
18. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59-65
19. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, et al. 2011. Enterotypes of the human gut microbiome. Nature 473:174-80
20. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, et al. 2011. European expert opinion on the management of invasive candidiasis in adults. Clin. Microbiol. Infect. 17(Suppl. 5):1-12
21. Gabaldon T, Martin T, Marcet-Houben M, Durrens P, Bolotin-Fukuhara M, et al. 2013. Comparative genomics of emerging pathogens in the Candida glabrata clade. BMC Genom. 14:623
22. Angoulvant A, Guitard J, Hennequin C. 2016. Old and new pathogenic Nakaseomyces species: epidemiology, biology, identification, pathogenicity and antifungal resistance. FEMS Yeast Res. 16:fov114
23. Latge JP. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-50
24. Thomas PA, Kaliamurthy J. 2013. Mycotic keratitis: epidemiology, diagnosis and management. Clin. Microbiol. Infect. 19:210-20
25. Pitt JI, Samson RA. 2007. Nomenclatural considerations in naming species of Aspergillus and its teleomorphs. Stud. Mycol. 59:67-70
26. Nucci M, Anaissie E. 2007. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 20:695-704
27. Bensch K, Braun U, Groenewald JZ, Crous PW. 2012. The genus Cladosporium. Stud. Mycol. 72:1-401
28. Sandoval-Denis M, Sutton DA, Martin-Vicente A, Cano-Lira JF,Wiederhold N, et al. 2015. Cladosporium species recovered from clinical samples in the United States. J. Clin. Microbiol. 53:2990-3000
29. Vacher G, Niculita-Hirzel H, Roger T. 2015. Immune responses to airborne fungi and non-invasive airway diseases. Semin. Immunopathol. 37:83-96
30. Amend A. 2014. From dandruff to deep-sea vents: Malassezia-like fungi are ecologically hyper-diverse. PLOS Pathog. 10:e1004277
31. Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. 2015. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLOS Pathog. 11:e1004523
32. Hooper LV, Littman DR, Macpherson AJ. 2012. Interactions between the microbiota and the immune system. Science 336:1268-73
33. McFarland LV. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 16:2202-22
34. McFarland LV, Surawicz CM,Greenberg RN, Fekety R, ElmerGW, et al. 1994. A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271:1913-18
35. Batista TM, Marques ET Jr., Franco GR, Douradinha B. 2014. Draft genome sequence of the probiotic yeast Saccharomyces cerevisiae var. boulardii strain ATCC MYA-796. Genome Announc. 2(6):01345-14
36. Castagliuolo I,Riegler MF, Valenick L, LaMont JT,Pothoulakis C. 1999. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect. Immun. 67:302-7
37. Buts JP,Dekeyser N, StilmantC,Delem E, Smets F, Sokal E. 2006. Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr. Res. 60:24-29
38. Ducluzeau R, Bensaada M. 1982. Effet compare de l'administration unique ou en continu de Saccharomyces boulardii sur l'etablissement de diverses souches de Candida dans le tractus digestif de souris gnotoxeniques [Comparative effect of a single or continuous administration of Saccharomyces boulardii on the establishment of various strains of Candida in the digestive tract of gnotobiotic mice]. Ann. Microbiol. 133:491-501
39. Zbinden R, Gonczi EE, Altwegg M. 1999. Inhibition of Saccharomyces boulardii (nom. inval.) on cell invasion of Salmonella typhimurium and Yersinia enterocolitica. Microb. Ecol. Health Dis. 11:158-62
40. QamarA,Aboudola S,Warny M, Michetti P, Pothoulakis C, et al. 2001. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect. Immun. 69:2762-65
41. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC. 2011. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 301:G1083-92
42. Guslandi M, Mezzi G, Sorghi M, Testoni PA. 2000. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. 45:1462-64
43. Plein K, Hotz J. 1993. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-A pilot study. Z. Gastroenterol. 31:129-34
44. Guslandi M, Giollo P, Testoni PA. 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 15:697-98
45. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, et al. 2006. Saccharomyces boulardii inhibits inflammatory bowel disease by trappingTcells in mesenteric lymph nodes. Gastroenterology 131:1812-25
46. Jawhara S, Poulain D. 2007. Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med. Mycol. 45:691-700
47. Wu X, Vallance BA, Boyer L, Bergstrom KS, Walker J, et al. 2008. Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am. J. Physiol. Gastrointest. Liver Physiol. 294:G295-306
48. Takata K, Tomita T, Okuno T, Kinoshita M, Koda T, et al. 2015. Dietary yeasts reduce inflammation in central nerve system via microflora. Ann. Clin. Transl. Neurol. 2:56-66
49. Hoffmann C, Dollive S, Grunberg S, Chen J, Li H, et al. 2013. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. PLOS ONE 8:e66019
50. Findley K, Oh J, Yang J, Conlan S, Deming C, et al. 2013. Topographic diversity of fungal and bacterial communities in human skin. Nature 498:367-70
51. Rizzetto L, IfrimDC, Moretti S, Tocci N, Cheng SC, et al. 2016. Fungal chitin induces trained immunity in humanmonocytes during cross-talk of the hostwith Saccharomyces cerevisiae. J. Biol. Chem. 291:7961-72
52. Quintin J, Saeed S, Martens JH, Giamarellos-Bourboulis EJ, Ifrim DC, et al. 2012. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12:223-32
53. Wagener J, Malireddi RK, Lenardon MD, Koberle M, Vautier S, et al. 2014. Fungal chitin dampens inflammation through IL-10 induction mediated by NOD2 and TLR9 activation. PLOS Pathog. 10:e1004050
54. Zhang Z, Li J, Zheng W, Zhao G, Zhang H, et al. 2016. Peripheral lymphoid volume expansion and maintenance are controlled by gut microbiota via RALDH+ dendritic cells. Immunity 44:330-42
55. Bauer H, Horowitz RE, Levenson SM, Popper H. 1963. The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. Am. J. Pathol. 42:471-83
56. De Jesus M, Rodriguez AE, Yagita H, Ostroff GR, Mantis NJ. 2015. Sampling of Candida albicans and Candida tropicalis by Langerin-positive dendritic cells in mouse Peyer's patches. Immunol. Lett. 168:64-72
57. Wheeler ML, Bar AS, Leal CA, Tang J, Brown J, et al. 2016. Immunological consequences of intestinal fungal dysbiosis. Cell Host Microbe 19(6):865-73
58. Bacher P, Kniemeyer O, Schonbrunn A, Sawitzki B, Assenmacher M, et al. 2014. Antigen-specific expansion of human regulatory T cells as a major tolerance mechanism against mucosal fungi. Mucosal Immunol. 7:916-28
59. Bonifazi P, Zelante T, D'Angelo C, De Luca A, Moretti S, et al. 2009. Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol. 2:362-74
60. Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, et al. 2010. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat. Immunol. 11:846-53
61. HaubenE,Gregori S, Draghici E, Migliavacca B, Olivieri S, et al. 2008. Activation of the aryl hydrocarbon receptor promotes allograft-specific tolerance through direct and dendritic cell-mediated effects on regulatory T cells. Blood 112:1214-22
62. Pierce JV, Kumamoto CA. 2012. Variation in Candida albicans EFG1 expression enables host-dependent changes in colonizing fungal populations. mBio 3:e00117-12
63. Tyc KM,Herwald SE,Hogan JA, Pierce JV, Klipp E,KumamotoCA. 2016. The game theory of Candida albicans colonization dynamics reveals host status-responsive gene expression. BMC Syst. Biol. 10:20
64. Zelante T, Iannitti RG, De Luca A, Arroyo J, Blanco N, et al. 2012. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat. Commun. 3:683
65. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG,White TC. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv13
66. WisplinghoffH, BischoffT,Tallent SM, SeifertH,Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-17
67. Li Z, Jiang C, Dong D, Zhang L, Tian Y, et al. 2016. The correlation between Candida colonization of distinct body sites and invasive candidiasis in emergency intensive care units: statistical and molecular biological analysis. Mycopathologia 181(7-8):475-84
68. Gouba N, DrancourtM. 2015. Digestive tract mycobiota: a source of infection. Med. Mal. Infect. 45:9-16
69. Miranda LN, van der Heijden IM, Costa SF, Sousa AP, Sienra RA, et al. 2009. Candida colonisation as a source for candidaemia. J. Hosp. Infect. 72:9-16
70. Nucci M, Anaissie E. 2001. Revisiting the source of candidemia: skin or gut? Clin. Infect. Dis. 33:1959-67
71. Kullberg BJ, Arendrup MC. 2015. Invasive candidiasis. N. Engl. J. Med. 373:1445-56
72. Sobel JD. 2007. Vulvovaginal candidosis. Lancet 369:1961-71
73. Tajima M, Sugita T, Nishikawa A, Tsuboi R. 2008. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J. Investig. Dermatol. 128:345-51
74. Kaneko T, Murotani M, Ohkusu K, Sugita T, Makimura K. 2012. Genetic and biological features of catheter-associated Malassezia furfur from hospitalized adults. Med. Mycol. 50:74-80
75. Curvale-Fauchet N, Botterel F, Legrand P, Guillot J, Bretagne S. 2004. Frequency of intravascular catheter colonization by Malassezia spp. in adult patients. Mycoses 47:491-94
76. Trick WE, Fridkin SK, Edwards JR,Hajjeh RA, Gaynes RP,Natl. Nosocom. Infections Surveill. System Hospitals. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:627-30
77. Koh AY, Kohler JR, Coggshall KT, Van Rooijen N, Pier GB. 2008. Mucosal damage and neutropenia are required for Candida albicans dissemination. PLOS Pathog. 4:e35
78. Kozel TR. 1996. Activation of the complement system by pathogenic fungi. Clin.Microbiol. Rev. 9:34-46
79. Ram S, Lewis LA, Rice PA. 2010. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin. Microbiol. Rev. 23:740-80
80. van Bruggen R, Drewniak A, Jansen M, van Houdt M, Roos D, et al. 2009. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for β-glucan-bearing particles. Mol. Immunol. 47:575-81
81. Soloviev DA, Fonzi WA, Sentandreu R, Pluskota E, Forsyth CB, et al. 2007. Identification of pHregulated antigen 1 released from Candida albicans as the major ligand for leukocyte integrin αMβ2. J. Immunol. 178:2038-46
82. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. 2001. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin. Infect. Dis. 32:1713-17
83. Lehrer RI, ClineMJ. 1969. Leukocytemyeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J. Clin. Investig. 48:1478-88
84. Winkelstein JA, Marino MC, Johnston RB Jr., Boyle J, Curnutte J, et al. 2000. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 79:155-69
85. Swamydas M, Gao JL, Break TJ, Johnson MD, Jaeger M, et al. 2016. CXCR1-mediated neutrophil degranulation and fungal killing promote Candida clearance and host survival. Sci. Transl.Med. 8:322ra10
86. Amulic B, Cazalet C, Hayes GL, Metzler KD, Zychlinsky A. 2012. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30:459-89
87. Wozniok I,Hornbach A, SchmittC, FroschM,Einsele H, et al. 2008. Induction of ERK-kinase signalling triggers morphotype-specific killing of Candida albicans filaments by human neutrophils. Cell. Microbiol. 10:807-20
88. Ermert D, NiemiecMJ, Rohm M, Glenthoj A, Borregaard N, Urban CF. 2013. Candida albicans escapes from mouse neutrophils. J. Leukoc. Biol. 94:223-36
89. Lionakis MS, Lim JK, Lee CC, Murphy PM. 2011. Organ-specific innate immune responses in a mouse model of invasive candidiasis. J. Innate Immun. 3:180-99
90. Lionakis MS, Fischer BG, Lim JK, Swamydas M, Wan W, et al. 2012. Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis. PLOS Pathog. 8:e1002865
91. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, et al. 2010. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115:1519-29
92. Hunniger K, Lehnert T, Bieber K, Martin R, Figge MT, Kurzai O. 2014. A virtual infection model quantifies innate effector mechanisms and Candida albicans immune escape in humanblood.PLOS Comput. Biol. 10:e1003479
93. Qian Q, Jutila MA, Van Rooijen N, Cutler JE. 1994. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J. Immunol. 152:5000-8
94. Ngo LY, Kasahara S, Kumasaka DK, Knoblaugh SE, Jhingran A,Hohl TM. 2014. Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis. J. Infect. Dis. 209:109-19
95. Lionakis MS, Swamydas M, Fischer BG, Plantinga TS, Johnson MD, et al. 2013. CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J. Clin. Investig. 123:5035-51
96. MajerO, BourgeoisC,Zwolanek F, Lassnig C, Kerjaschki D, et al. 2012. Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections. PLOS Pathog. 8:e1002811
97. Bar E,Whitney PG,Moor K, Reis e Sousa C, LeibundGut-Landmann S. 2014. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40:117-27
98. Whitney PG, Bar E, Osorio F, Rogers NC, Schraml BU, et al. 2014. Syk signaling in dendritic cells orchestrates innate resistance to systemic fungal infection. PLOS Pathog. 10:e1004276
99. Voigt J, Hunniger K, Bouzani M, Jacobsen ID, Barz D, et al. 2014. Human natural killer cells acting as phagocytes against Candida albicans and mounting an inflammatory response that modulates neutrophil antifungal activity. J. Infect. Dis. 209:616-26
100. Lionakis MS. 2012. Genetic susceptibility to fungal infections in humans. Curr. Fungal Infect. Rep. 6:11-22
101. Lavigne LM, Schopf LR, Chung CL,Maylor R, Sypek JP. 1998. The role of recombinant murine IL-12 and IFN-γin the pathogenesis of a murine systemic Candida albicans infection. J. Immunol. 160:284-92
102. Balish E, Wagner RD, Vazquez-Torres A, Pierson C, Warner T. 1998. Candidiasis in interferon-γ knockout (IFN-γ-/-) mice. J. Infect. Dis. 178:478-87
103. Netea MG, Vonk AG, van den Hoven M, Verschueren I, Joosten LA, et al. 2003. Differential role of IL-18 and IL-12 in the host defense against disseminated Candida albicans infection. Eur. J. Immunol. 33:3409-17
104. Kashem SW, Igyarto BZ, Gerami-Nejad M, Kumamoto Y, Mohammed J, et al. 2015. Candida albicans morphology and dendritic cell subsets determine T helper cell differentiation. Immunity 42:356-66
105. Johnson MD, Plantinga TS, van Vosse E, Velez Edwards DR, Smith PB, et al. 2012. Cytokine gene polymorphisms and the outcome of invasive candidiasis: a prospective cohort study. Clin. Infect. Dis. 54:502-10
106. Grice EA, Segre JA. 2011. The skin microbiome. Nat. Rev. Microbiol. 9:244-53
107. Hannigan GD, Meisel JS, Tyldsley AS, Zheng Q, Hodkinson BP, et al. 2015. The human skin doublestranded DNA virome: topographical and temporal diversity, genetic enrichment, and dynamic associations with the host microbiome. mBio 6:e01578-15
108. Sanford JA, Gallo RL. 2013. Functions of the skin microbiota in health and disease. Semin. Immunol. 25:370-77
109. Naik S, Bouladoux N, Wilhelm C, Molloy MJ, Salcedo R, et al. 2012. Compartmentalized control of skin immunity by resident commensals. Science 337:1115-19
110. Brasch J, Christophers E. 1993. Azelaic acid has antimycotic properties in vitro. Dermatology 186:55-58
111. Mayser P. 2015. Medium chain fatty acid ethyl esters-activation of antimicrobial effects by Malassezia enzymes. Mycoses 58:215-19
112. Furusawa Y, Obata Y, Fukuda S, Endo TA,NakatoG, et al. 2013. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504:446-50
113. Arpaia N, Campbell C, FanX,Dikiy S, van der Veeken J, et al. 2013. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504:451-55
114. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, et al. 2013. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569-73
115. Stalhberger T, Simenel C, Clavaud C, Eijsink VG, Jourdain R, et al. 2014. Chemical organization of the cell wall polysaccharide core of Malassezia restricta. J. Biol. Chem. 289:12647-56
116. Ishikawa T, Itoh F, Yoshida S, Saijo S, Matsuzawa T, et al. 2013. Identification of distinct ligands for the C-type lectin receptors Mincle and Dectin-2 in the pathogenic fungus Malassezia. Cell Host Microbe 13:477-88
117. Selander C, Engblom C, Nilsson G, Scheynius A, Andersson CL. 2009. TLR2/MyD88-dependent and-independent activation of mast cell IgE responses by the skin commensal yeast Malassezia sympodialis. J. Immunol. 182:4208-16
118. Gaitanis G, Magiatis P, HantschkeM, Bassukas ID, Velegraki A. 2012. The Malassezia genus in skin and systemic diseases. Clin. Microbiol. Rev. 25:106-41
119. Gaitanis G, Velegraki A, Mayser P, Bassukas ID. 2013. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin. Dermatol. 31:455-63
120. Mexia N, Gaitanis G, Velegraki A, Soshilov A, Denison MS, Magiatis P. 2015. Pityriazepin and other potent AhR ligands isolated from Malassezia furfur yeast. Arch. Biochem. Biophys. 571:16-20
121. Magiatis P, Pappas P, Gaitanis G, Mexia N, Melliou E, et al. 2013. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J. Investig. Dermatol. 133:2023-30
122. Barouti N, Mainetti C, Fontao L, Sorg O. 2015. L-Tryptophan as a novel potential pharmacological treatment for wound healing via aryl hydrocarbon receptor activation. Dermatology 230:332-39
123. Bock KW, Kohle C. 2009. The mammalian aryl hydrocarbon (Ah) receptor: from mediator of dioxin toxicity toward physiological functions in skin and liver. Biol. Chem. 390:1225-35
124. Di Meglio P, Duarte JH, Ahlfors H, Owens ND, Li Y, et al. 2014. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 40:989-1001
125. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, et al. 2008. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453:106-9
126. Vlachos C, Schulte BM, Magiatis P, Adema GJ, Gaitanis G. 2012. Malassezia-derived indoles activate the aryl hydrocarbon receptor and inhibit Toll-like receptor-induced maturation in monocyte-derived dendritic cells. Br. J. Dermatol. 167:496-505
127. Kadow S, Jux B, Zahner SP, Wingerath B, Chmill S, et al. 2011. Aryl hydrocarbon receptor is critical for homeostasis of invariant γδT cells in the murine epidermis. J. Immunol. 187:3104-10
128. Zhang E, Tanaka T, Tajima M, Tsuboi R, Nishikawa A, Sugita T. 2011. Characterization of the skin fungal microbiota in patientswith atopic dermatitis and in healthy subjects. Microbiol. Immunol. 55:625-32
129. Marcinkiewicz M, Majewski S. 2016. The role of antimicrobial peptides in chronic inflammatory skin diseases. Postep. Dermatol. Alergol. 33:6-12
130. Rapala-Kozik M, Bochenska O, Zawrotniak M, Wolak N, Trebacz G, et al. 2015. Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans. Infect. Immun. 83:2518-30
131. Lopez CM, Wallich R, Riesbeck K, Skerka C, Zipfel PF. 2014. Candida albicans uses the surface protein Gpm1 to attach to human endothelial cells and to keratinocytes via the adhesive protein vitronectin. PLOS ONE 9:e90796
132. Ran Y, Yamazaki M, Tsuboi R, Ogawa H. 2014. Adherence and proliferation of keratinocytes cultured with Candida albicans. J. Dermatol. 41:554-56
133. Mohammed J, Beura LK, Bobr A, Astry B, Chicoine B, et al. 2016. Stromal cells control the epithelial residence of DCs and memory T cells by regulated activation of TGF-and beta;. Nat. Immunol. 17:414-21
134. Kaplan DH. 2010. In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol. 31:446-51
135. Igyarto BZ, Haley K, Ortner D, Bobr A, Gerami-Nejad M, et al. 2011. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity 35:260-72
136. Kashem SW, RiedlMS, YaoC,Honda CN,Vulchanova L, Kaplan DH. 2015. Nociceptive sensory fibers drive interleukin-23 production from CD301b+ dermal dendritic cells and drive protective cutaneous immunity. Immunity 43:515-26
137. Riol-Blanco L, Ordovas-Montanes J, Perro M, Naval E, Thiriot A, et al. 2014. Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation. Nature 510:157-61
138. Cassone A, Cauda R. 2012. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 26:1457-72
139. Mukherjee PK, Chandra J, Retuerto M, Sikaroodi M, Brown RE, et al. 2014. Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. PLOS Pathog. 10:e1003996
140. Moyes DL, Wilson D, Richardson JP,Mogavero S,Tang SX, et al. 2016. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature 532:64-68
141. Kirkpatrick CH. 2001. Chronic mucocutaneous candidiasis. Pediatr. Infect. Dis. J. 20:197-206
142. Puel A, Cypowyj S, Marodi L, Abel L, Picard C, Casanova JL. 2012. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr. Opin. Allergy Clin. Immunol. 12:616-22
143. Gaffen SL, Jain R, Garg AV, Cua DJ. 2014. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat. Rev. Immunol. 14:585-600
144. Minegishi Y. 2009. Hyper-IgE syndrome. Curr. Opin. Immunol. 21:487-92
145. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, et al. 2009. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361:1760-67
146. Glocker EO, Hennigs A, Nabavi M, Schaffer AA, Woellner C, et al. 2009. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361:1727-35
147. McGovern DP, Kugathasan S, Cho JH. 2015. Genetics of inflammatory bowel diseases. Gastroenterology 149:1163-76
148. Joossens S, Reinisch W, Vermeire S, Sendid B, Poulain D, et al. 2002. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 122:1242-47
149. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, et al. 2012. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119-24
150. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, et al. 2011. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat. Genet. 43:1066-73
151. Ott SJ, Kuhbacher T, Musfeldt M, Rosenstiel P, Hellmig S, et al. 2008. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand. J. Gastroenterol. 43:831-41
152. Becker KL, Ifrim DC, Quintin J, Netea MG, van Veerdonk FL. 2015. Antifungal innate immunity: recognition and inflammatory networks. Semin. Immunopathol. 37:107-16
153. Cunha C, Di Ianni M, Bozza S, Giovannini G, Zagarella S, et al. 2010. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient-and donor-dependent mechanisms of antifungal immunity. Blood 116:5394-402
154. Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, et al. 2007. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat. Immunol. 8:39-46
155. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, et al. 2007. Dectin-1 is required for β-glucan recognition and control of fungal infection. Nat. Immunol. 8:31-38
156. Kerscher B, Willment JA, Brown GD. 2013. The Dectin-2 family of C-type lectin-like receptors: an update. Int. Immunol. 25:271-77
157. Ifrim DC, Bain JM, Reid DM, OostingM, Verschueren I, et al. 2014. Role of Dectin-2 for host defense against systemic infection with Candida glabrata. Infect. Immun. 82:1064-73
158. Zhu LL, Zhao XQ, Jiang C, You Y, Chen XP, et al. 2013. C-type lectin receptorsDectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. Immunity 39:324-34
159. Wells CA, Salvage-Jones JA, Li X, Hitchens K, Butcher S, et al. 2008. Themacrophage-inducible C-type lectin,Mincle, is an essential component of the innate immune response to Candida albicans. J. Immunol. 180:7404-13
160. Yamasaki S, Matsumoto M, Takeuchi O, Matsuzawa T, Ishikawa E, et al. 2009. C-type lectin Mincle is an activating receptor for pathogenic fungus, Malassezia. PNAS 106:1897-902
161. Sainz J, Lupianez CB, Segura-Catena J, Vazquez L, Rios R, et al. 2012. Dectin-1 and DC-SIGN polymorphisms associated with invasive pulmonary Aspergillosis infection. PLOS ONE 7:e32273
162. de Jong MA, Geijtenbeek TB. 2010. Langerhans cells in innate defense against pathogens. Trends Immunol. 31:452-59
163. Dan JM, Kelly RM, Lee CK, Levitz SM. 2008. Role of the mannose receptor in a murine model of Cryptococcus neoformans infection. Infect. Immun. 76:2362-67
164. Netea MG, Van Der Graaf CA, Vonk AG, Verschueren I, Van Der Meer JW, Kullberg BJ. 2002. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 185:1483-89
165. Plantinga TS, Johnson MD, Scott WK, van Vosse E, Velez Edwards DR, et al. 2012. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J. Infect. Dis. 205:934-43
166. Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, et al. 2005. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann. N. Y. Acad. Sci. 1062:95-103
167. Zarember KA, Godowski PJ. 2002. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168:554-61
168. Bochud PY, Chien JW, Marr KA, Leisenring WM, Upton A, et al. 2008. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 359:1766-77
169. Linden JR, Paepe ME, Laforce-Nesbitt SS, Bliss JM. 2013. Galectin-3 plays an important role in protection against disseminated candidiasis. Med. Mycol. 51:641-51
170. Chen HY, Liu FT, Yang RY. 2005. Roles of galectin-3 in immune responses. Arch. Immunol. Ther. Exp. 53:497-504
171. Means TK, Mylonakis E, Tampakakis E, Colvin RA, Seung E, et al. 2009. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J. Exp. Med. 206:637-53
172. Soloviev DA, Jawhara S, Fonzi WA. 2011. Regulation of innate immune response to Candida albicans infections by αMβ2-Pra1p interaction. Infect. Immun. 79:1546-58
173. DondersGG,BabulaO,BellenG,Linhares IM,Witkin SS. 2008. Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis. BJOG 115:1225-31
174. Granell M, Urbano-Ispizua A, Suarez B, Rovira M, Fernandez-Aviles F, et al. 2006. Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp. Hematol. 34:1435-41
175. Cunha C, Aversa F, Lacerda JF, Busca A,Kurzai O, et al. 2014. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N. Engl. J. Med. 370:421-32
176. Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, et al. 2002. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 420:182-86
177. Garlanda C, Bottazzi B, Bastone A, Mantovani A. 2005. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23:337-66